Abstracts Archive - Page 1118 of 2425 - ACR Meeting Abstracts

Abstract Number: 1701 • 2018 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
Ruta Tesfamicael¹, Harrison Lam², Oria Lu², Ratushtar Kapadia¹, Caroline Siegel¹, Lori Sahakian¹, Jennifer M. Grossman^1,3 and Maureen A. McMahon^1,4, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los angeles, CA, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease that can cause multisystem inflammation and damage. There are currently no widely agreed upon targets for…
Abstract Number: 1702 • 2018 ACR/ARHP Annual Meeting
Utility of the Avise Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression of Disease
Emily Liang¹, Mihaela Taylor² and Maureen A. McMahon³, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The AVISE Connective Tissue Disease test is a newly approved, commercially available test that combines autoantibody and biomarker levels to help diagnose systemic lupus…
Abstract Number: 1703 • 2018 ACR/ARHP Annual Meeting
Fragmented Qrs in Patients with Systemic Lupus Erythematosus: Relation to the Disease Activity: A Cross-Sectional Study
Masahiro Hosonuma, Nobuyuki Yajima, Ryo Yanai and Ryo Takahashi, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Cardiovascular disease is an important contributor to mortality in Systemic Lupus Erythematosus (SLE). It has been reported that disease activity at diagnosis was associated…
Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Ioannis Parodis^1,2, Sharzad Emamikia^1,2, Iva Gunnarsson^1,2, Ronald F. van Vollenhoven^2,3 and Katerina Chatzidionysiou^1,4, ¹Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Amsterdam Rheumatology and Immunology Center ARC, Department of Clinical Immunology & Rheumatology, University of Amsterdam, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…
Abstract Number: 1705 • 2018 ACR/ARHP Annual Meeting
Trajectory Analysis of Combined Disease Activity and Physical Component Summary Scale in an Inception Cohort of Adults with Systemic Lupus Erythematosus: Latent Classes Inform Different Patterns
William Fung¹, Lily Lim², George A. Tomlinson³, Lisa Engel⁴, Jiandong Su⁴ and Zahi Touma⁴, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: For patients with SLE, disease status, physical functioning, and participation in daily activities affect health-related quality of life. This study aims to: 1) describe…
Abstract Number: 1706 • 2018 ACR/ARHP Annual Meeting
Development of an Online Lupus Self-Management Program Based on the Transtheoretical Model of Change
Sarah Gilman¹, Deborah Levesque², Carol Cummins², Daniel J. Wallace³, Victoria P. Werth^4,5, Rosalind Ramsey-Goldman⁶, Margaret Kaniewski⁷ and Patricia Davidson⁸, ¹Wayfinder Health Strategies, Falls Church, VA, ²ProChange Behavior Systems Inc., West Kingston, RI, ³Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ⁴Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶FSM, Northwestern University, Chicago, IL, ⁷Centers for Disease Control & Prevention, Atlanta, GA, ⁸Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 3 of a 5-year cooperative agreement with the Centers for Disease Control and Prevention to develop…
Abstract Number: 1707 • 2018 ACR/ARHP Annual Meeting
Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive Patients
Olga Vera-Lastra¹, Cristopher Vázquez², María Pilar Cruz-Dominguez³ and Luis J. Jara-Quezada⁴, ¹Internal Medicine, Hospital de Especialidades Centro Medico nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ²Internal medicine Department, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ³Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico City, Mexico, ⁴Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico, Mexico
Background/Purpose: Prolactin has a role in pathogenesis of Systemic Lupus Erythematous (SLE); high levels have been associated with activity. In contrast, a decrease in dehydroepiandrosterone…
Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
Min-Hua Tseng¹ and Jing-Long Huang², ¹Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Medicine, Chang-Gung University, Taoyuan city, Taiwan
Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…
Abstract Number: 1709 • 2018 ACR/ARHP Annual Meeting
Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
Lindsey Warner and Shazia Beg, University of Central Florida College of Medicine, Orlando, FL
Background/Purpose: Lupus is an autoimmune disease with multitude of symptoms that are often not fully controlled by standard biomedical treatments. This study was designed to…
Abstract Number: 1710 • 2018 ACR/ARHP Annual Meeting
Polypharmacy in Older Adults with Systemic Lupus Erythematosus
Dale Seguin¹, Christine A. Peschken², Ruby Grymonpre³, Phil St. John⁴ and Annaliese Tisseverasinghe⁵, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³College of Pharmacology, University of Manitoba, Manitoba, MB, Canada, ⁴Geriatrics, University of Manitoba, Winnipeg, MB, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Polypharmacy is a strong risk factor for drug toxicity and adverse clinical outcomes, including delirium, falls, hospitalizations, and death. Polypharmacy is correlated with the…
Abstract Number: 1711 • 2018 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
Shereen Oon¹, Molla Huq², Vera Golder³, Emily Ong⁴, Eric Morand⁵ and Mandana Nikpour⁶, ¹The University of Melbourne at St Vincent's Hospital, Fitzroy, Australia, ²The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁴School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁶The University of Melbourne, Melbourne, Australia, Melbourne, Australia
Background/Purpose: Measurement of treatment response in SLE clinical trials has been based on measurement of change from baseline; however a treat-to-target analysis has seldom been…
Abstract Number: 1712 • 2018 ACR/ARHP Annual Meeting
Validation of Proposed EULAR/Acr SLE Classification Criteria Versus SLICC SLE Classification Criteria
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The SLICC 2012 SLE classification criteria and the revised ACR-11 criteria count each SLE manifestation equally. We validated the recently proposed EULAR/ACR classification rule…
Abstract Number: 1713 • 2018 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension
Eric Morand¹, Joan T. Merrill², David A. Isenberg³, Amy H. Kao⁴, Cristina Vazquez-Mateo⁴, Stephen Wax⁵, Peter Chang⁵, Kishore Pudota⁴, Cynthia Aranow⁶ and Daniel J. Wallace⁷, ¹Monash University, Melbourne, Australia, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University College London, London, United Kingdom, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁶The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Low disease activity (LDA) and remission are important goals in the treatment of patients (pts) with SLE.1,2 Lupus Low Disease Activity State (LLDAS) is…
Abstract Number: 1714 • 2018 ACR/ARHP Annual Meeting
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, R. Paola Daly¹, Leslie Hanrahan², Annick Anderson³, Kathleen Arntsen⁴, Sang-Cheol Bae⁵, Ian N. Bruce⁶, Karen Costenbader⁷, Thomas Dörner⁸, Amy H. Kao⁹, Susan Manzi¹⁰, Eric Morand¹¹, Sandra Raymond¹, Brad H. Rovin¹², Laura E. Schanberg¹³, Victoria P. Werth¹⁴, Joan Von Feldt¹⁵ and Kenneth Getz³, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Washington DC, DC, ³Tufts Center for the Study of Drug Development, Boston, MA, ⁴Lupus and Allied Diseases, Inc., Verona, NY, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹⁰Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ¹¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹²Ohio State University Medical Center, Columbus, OH, ¹³Duke University Medical Center, Durham, NC, ¹⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁵GlaxoSmithKline, Philadelphia, PA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus initiative seeking to identify and prioritize top barriers in lupus impacting…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].